ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Long-Term Real-World Evaluation of Tofacitinib's Effectiveness and Safety in Japan: Insights Into Optimal Timing for Dose Reduction.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Real-World Evaluation of Tofacitinib's Effectiveness and Safety in Japan: Insights Into Optimal Timing for Dose Reduction.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Tofacitinib (TOF), an oral pan-Janus kinase (JAK) inhibitor, is a therapeutic option for moderate to severe ulcerative colitis (UC). While short-term efficacy has been reported, its long-term real-world outcomes-particularly in Asian populations-and optimal dose reduction timing are incompletely understood. Methods and Results: This single-center, retrospective study included 63 patients with UC treated with TOF between October 2018 and April 2025. Clinical outcomes-response, remission, steroid-free remission, and adverse events-were assessed at Weeks 26, 52, and 104. The impact of dose reduction (20-10 mg/day) was analyzed, focusing on endoscopic mucosal healing (Mayo endoscopic subscore 0-1). At Week 26, clinical response and remission rates were 63% and 53%, respectively; 43% of patients achieved steroid-free remission by Week 52, and 41% maintained it at Week 104. Early responders were associated with treatment efficacy in a lower partial Mayo score (OR = 1.724, 95% CI: 0.994-2.988, Conclusion: TOF demonstrated sustained effectiveness and safety in UC. Mucosal healing was strongly associated with successful dose de-escalation, representing a key treatment target. These findings support treat-to-target strategies incorporating endoscopic assessment to guide TOF dose reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.